Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): results of an open-label, phase 1, multicohort study.
Saved in:
| Title: | Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): results of an open-label, phase 1, multicohort study. |
|---|---|
| Authors: | Hellmann, Matthew D1 hellmanm@mskcc.org, Rizvi, Naiyer A1, Goldman, Jonathan W2, Gettinger, Scott N3, Borghaei, Hossein4, Brahmer, Julie R5, Ready, Neal E6, Gerber, David E7, Chow, Laura Q8, Juergens, Rosalyn A9, Shepherd, Frances A10, Laurie, Scott A11, Geese, William J12, Agrawal, Shruti12, Young, Tina C12, Li, Xuemei12, Antonia, Scott J13 |
| Source: | Lancet Oncology. Jan2017, Vol. 18 Issue 1, p31-41. 11p. |
| Database: | Academic Search Ultimate |
Be the first to leave a comment!
